Floatz logo

bay2395840

Diabetic Neuropathic Pain

BayerPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

27 Active assets in the Diabetic Neuropathic Pain cohort.

Asset / SponsorPhaseRating
Duloxetine
Aga Khan University
Phase 4A
Duloxetine
Eli Lilly and Company
Phase 4BBB
ds-5565
Bangladesh Medical University
Phase 4BBB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
Capsaicin
Corporacion Parc Tauli
Phase 4BBB

View all 50 →

Same molecule, other indications

bay2395840 is also rated in:

diabetes mellitusDormant
B
Indicative ·
57 / 100
View asset →
peripheral neuropathyDormant
B
Indicative ·
57 / 100
View asset →
Healthy VolunteersDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →